TREATMENT-NAÏVE STUDIES
ADVERSE DRUG REACTIONS
Grades 2 to 4 treatment-emergent ADRs
(≥2% frequency in either treatment arm)1,2
Grade 1 insomnia rates
7% and 4% in patients receiving TIVICAY and efavirenz/TDF/FTC, respectively
These events were not treatment limiting
*Includes pooled terms: rash, rash generalized, rash macular, rash maculopapular, rash pruritic, and drug eruption.
Grades 2 to 4 treatment-emergent ADRs2,3*
Grade 1 insomnia rates
1% or <1% in patients receiving TIVICAY and raltegravir, respectively
These events were not treatment limiting
*From table 3 of the full PI for TIVICAY.
†Includes pooled terms: rash, rash generalized, rash macular, rash maculopapular, rash pruritic, and drug eruption.
Grades 2 to 4 treatment-emergent ADRs
(≥2% frequency in either treatment arm)2
Grade 1 insomnia rates2
1% and 2% in patients receiving TIVICAY and darunavir/ritonavir, respectively
These events were not treatment limiting
*Includes pooled terms: rash, rash generalized, rash macular, rash maculopapular, rash pruritic, and drug eruption.